Mark Forman

Mark Forman currently serves as Chief Medical Officer at Ventyx Biosciences, a position held since August 2024. Previously, Forman held the role of Chief Medical Officer at Passage Bio from July 2021 to July 2024 and served as Senior Director of Drug Development at the Alzheimer's Drug Discovery Foundation for a brief period in early 2021. Prior experience includes significant leadership roles in translational medicine and clinical pharmacology at ACADIA Pharmaceuticals and Merck, where Forman advanced through various positions, ultimately becoming Executive Director. Academic experience encompasses Assistant Professor of Neuropathology at the University of Pennsylvania and research positions at the institution. Forman's educational background includes an MD from Duke University School of Medicine, a PhD in Immunology from The Rockefeller University, and a BS in Biochemistry and Molecular Biology from Yale University.